Posaconazole 12 mg/kg/day BID + Posaconazole 18 mg/kg/day BID + Posaconazole 18 mg/kg/day TID + Posaconazole 12 mg/kg/day TID
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fungal Infections
Conditions
Fungal Infections
Trial Timeline
Apr 17, 2008 → Apr 1, 2015
NCT ID
NCT01716234About Posaconazole 12 mg/kg/day BID + Posaconazole 18 mg/kg/day BID + Posaconazole 18 mg/kg/day TID + Posaconazole 12 mg/kg/day TID
Posaconazole 12 mg/kg/day BID + Posaconazole 18 mg/kg/day BID + Posaconazole 18 mg/kg/day TID + Posaconazole 12 mg/kg/day TID is a phase 1 stage product being developed by Merck for Fungal Infections. The current trial status is terminated. This product is registered under clinical trial identifier NCT01716234. Target conditions include Fungal Infections.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01716234 | Phase 1 | Terminated |
Competing Products
20 competing products in Fungal Infections
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BSG005 | Alkem Laboratories | Phase 1/2 | 41 |
| Micafungin | Astellas Pharma | Phase 1 | 33 |
| Micafungin | Astellas Pharma | Pre-clinical | 23 |
| amphotericin B liposomal (Ambisome) | Astellas Pharma | Approved | 85 |
| Parenteral micafungin application + Other parenteral antifungal drugs | Astellas Pharma | Pre-clinical | 23 |
| Isavuconazonium sulfate + Voriconazole + Posaconazole | Astellas Pharma | Pre-clinical | 23 |
| Micafungin | Astellas Pharma | Pre-clinical | 23 |
| Micafungin | Astellas Pharma | Pre-clinical | 23 |
| Fluconazole | Astellas Pharma | Pre-clinical | 23 |
| Micafungin | Astellas Pharma | Phase 1 | 33 |
| Micafungin + Placebo | Astellas Pharma | Phase 3 | 77 |
| Posaconazole + Voriconazole + Placebo | Merck | Phase 3 | 77 |
| caspofungin acetate + Comparator: Micafungin sodium | Merck | Phase 3 | 77 |
| caspofungin acetate | Merck | Phase 3 | 77 |
| Posaconazole | Merck | Phase 1 | 33 |
| Posaconazole | Merck | Approved | 85 |
| Posaconazole IV 6 mg/kg + Posaconazole PFS 6 mg/kg | Merck | Phase 2 | 52 |
| Posaconazole oral suspension 40 mg/mL | Merck | Pre-clinical | 23 |
| caspofungin acetate | Merck | Phase 2 | 52 |
| Posaconazole | Merck | Phase 1 | 33 |